Shares of Nevro NVRO moved lower in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 52.27% year over year to ($0.21), which beat the estimate of ($0.33).
Revenue of $109,731,000 declined by 4.06% from the same period last year, which beat the estimate of $107,430,000.
Guidance
Nevro Sees Q1 Sales Of $84M-$86M Vs $94.23M Estimates
Conference Call Details
Date: Feb 24, 2021
Time: 04:30 PM
Technicals
Company's 52-week high was at $188.14
Company's 52-week low was at $65.05
Price action over last quarter: Up 6.73%
Company Profile
Nevro Corp is a medical device company. Its key product is the Senza spinal cord stimulation system, a neuromodulation platform for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro generates the majority of its revenue in the United States. It also receives nearly half of its revenue from Australia, the United Kingdom, and Germany.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.